Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2018

View Archived Issues

Aduro earns milestone from Merck & Co. for initiation of phase I trial of anti-CD27 antibody

Caladrius Biosciences acquires license to late-stage CD34+ cell therapy program from Shire

Eisai and Purdue Pharma report results from clinical studies of lemborexant

Pivotal phase III study of bempedoic acid in ASCVD meets primary endpoint

Vocimagene amiretrorepvec/5-fluorocytosine granted E.U. orphan designation for glioma

Researchers evaluate safety and immunogenicity of a new anti-allergic vaccine

MD Anderson Cancer Center and Berkeley Lights launch new company

Phase IIb study of BTK inhibitor in MS meets primary endpoint

Oxford Vacmedix closes series A funding to develop its two lead cancer vaccine candidates

NTP-42 receives E.U., U.S. orphan designations for pulmonary arterial hypertension

Compugen licenses SUREtechnology platform from Selexis

Antimicrobial polymers show killing activity without leading to resistance

University of Bristol presents new alpha4beta2 nicotinic receptor partial agonists

Novel NF-kappaB inhibitors synthesized at University College Dublin

Arena Pharmaceuticals patents new 5-HT2C receptor agonists

Genoimmune Therapeutics creates novel human leukocyte antigen-binding polypeptides

New polynucleotides encoding semaphorin-6 synthesized at Kanazawa University

Evotec and Sanofi in negotiations over new open innovation platform in infectious disease

Eisai and Merck & Co. agree on strategic collaboration for Lenvima

Harbin Medical University presents data on PET tracer for EGFR mutation determination

Immuron announces topline phase II results for IMM-124E in NASH

MuSK stimulation preserves neuromuscular synapses in amyotrophic lateral sclerosis

Medicure to commercialize Zydus Cadila's pitavastatin in U.S.

Daiichi Sankyo initiates phase II study of DS-8201 in HER2-expressing colorectal cancer

Aevi Genomic Medicine and Kyowa Hakko Kirin expand collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...